Geode Capital Management’s Turnstone Biologics TSBX Stock Holding History

Geode Capital Management’s Portfolio TSBX Stock Details TSBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-130,077	Closed	-$46.7K	–	4566
2025 Q2	$46.7K	Sell	130,077 -6,703	-5%	-$2.35K	﹤0.01%	4234
2025 Q1	$56.1K	Sell	136,780 -1,879	-1%	-$800	﹤0.01%	4176
2024 Q4	$68.6K	Buy	138,659 +5,840	+4%	+$2.88K	﹤0.01%	4186
2024 Q3	$74K	Buy	132,819 +60,867	+85%	+$93.4K	﹤0.01%	4175
2024 Q2	$189K	Sell	71,952 -166,132	-70%	-$475K	﹤0.01%	3928
2024 Q1	$624K	Buy	238,084 +116,148	+95%	+$332K	﹤0.01%	3530
2023 Q4	$310K	Buy	121,936 +11,441	+10%	+$29.9K	﹤0.01%	3789
2023 Q3	$435K	Buy	+110,495	New	+$985K	﹤0.01%	3652

Geode Capital Management's TSBX Position: Q3 2025 in Review

Geode Capital Management sold out of Turnstone Biologics (TSBX) in Q3 2025, closing a stake of 130,077 shares — an estimated $46.7K sold.

Geode Capital Management first reported a position in TSBX in Q3 2023 and held it in 8 quarters. The position peaked at $624K in Q1 2024. 1 fund tracked by Wall St. Rank holds TSBX as of Q3 2025.

Geode Capital Management reported no remaining Turnstone Biologics position as of Q3 2025 after selling out during the quarter.
Geode Capital Management sold 130,077 Turnstone Biologics shares in Q3 2025, an estimated $46.7K.
Geode Capital Management first reported a position in Turnstone Biologics in Q3 2023 and held it in 8 quarters.
Geode Capital Management's Turnstone Biologics position peaked at $624K in Q1 2024.
1 fund tracked by Wall St. Rank held Turnstone Biologics as of Q3 2025.

Based on Geode Capital Management's 13F filing for Q3 2025, filed 12 Nov 2025.